Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085956
Status:
COMPLETED
Last Update Posted:
2007-03-09
First Post:
2004-06-18
Brief Title:
Effects of Arzoxifene on Bone Mass and the Uterus
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine
The effects of arzoxifene on bone mineral density bone mass at the spine and hip in postmenopausal women
The effects of arzoxifene on the uterus womb in postmenopausal women
The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density
The effects of arzoxifene on blood lipids fats and other blood markers of heart disease risk
The safety of arzoxifene and any side effects that might be associated with its use
The effects of arzoxifene on bone mineral density bone mass at the spine and hip in postmenopausal women
The effects of arzoxifene on the uterus womb in postmenopausal women
The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density
The effects of arzoxifene on blood lipids fats and other blood markers of heart disease risk
The safety of arzoxifene and any side effects that might be associated with its use
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H4Z-MC-GJAE | None | None | None |